Focused Cell and Gene Therapy Manufacturing
At OmniaBio, we are manufacturing a disease-free future through our relentless focus and deep expertise in cell and gene therapy manufacturing.
Facilities and Experts to Meet Your Timeline
We are the experts in lentiviral, genetically modified cells, and iPSC-based development through GMP manufacturing. Leveraging the established foundation and infrastructure of CCRM, we combine our deep expertise with cutting-edge technologies to facilitate the translation of novel cell- and gene-based therapeutics. Our capabilities range from early preclinical development and process development through to commercial-stage GMP manufacturing. Our collaborative and transparent approach to project management, combined with the seamless integration with analytical and regulatory support and phase-appropriate Quality Assurance, ensures your cell or gene therapy asset’s progression to the next developmental milestone.
Dependable and Consistent
We provide best-in-class services and comprehensive phase-specific consultation to support your cell and gene therapy development and manufacturing. When you partner with OmniaBio, you can access deep expertise to facilitate preclinical development, such as GMP iPSC reprogramming, gene editing and differentiation, through custom and high-throughput media development and process development to automate, close and maximize process performance. With the seamless integration of analytical and regulatory support, you can depend on us to consistently deliver as you scale up and scale out.
Capacity and Track Record
At OmniaBio, we possess the talent and state-of-the-art manufacturing facilities to ensure we deliver on time and on target.
Featured Case Study
Manufacturing of Pluripotent Stem Cell-Derived Cardiomyocytes for Pre-Clinical Animal Studies
In collaboration with Dr. Michael Laflamme’s lab at University Health Network, the conversion of a highly manual, partially-adherent process for stem cell-derived cardiomyocyte manufacturing was converted to a highly scalable and closed suspension-based process. This allowed for adequate numbers of differentiated cardiomyocytes to be generated for subsequent preclinical animal studies.
Manufacturing for Your CGT Needs
Best-in-class solutions for cell therapy development and manufacturing
Enhancing gene delivery through end-to-end developmental support
Industry-leading experience and capabilities in stem cell based therapies